Positive results from drug trials could boost Seattle Genetics' shares

08/20/2010 | Reuters

Positive results from clinical trials of Seattle Genetics' drug candidates for leukemia and lymphoma could make 2010 a milestone year for the biotech company, according to this Reuters analysis. The biotech firm is expected to reveal study data of lintuzumab, a treatment for acute myeloid leukemia, between later this month and October and brentuximab vedotin, a Hodgkin lymphoma drug, by late September.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory FDA
Cardinal Health
Columbus, OH
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA